The stability of mRNA encoding IL-4 is increased in pulmonary tuberculosis, while stability of mRNA encoding the antagonistic splice variant, IL-4δ2, is not

Tuberculosis

Volumn 87, Issue 3, 2007, Pages 237-241

  Dheda, Keertan ^a,b,c   Chang, Jung Su ^a   Huggett, Jim F ^a   Kim, Louise U ^a   Johnson, Margaret A ^b   Zumla, Alimuddin ^a   Rook, Graham A W ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Half life; Human; IL 4; IL 4 2; mRNA; Tuberculosis

Indexed keywords

DACTINOMYCIN; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; MESSENGER RNA; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INHIBITION; FEMALE; GENETIC CODE; GENETIC VARIABILITY; HUMAN; LUNG TUBERCULOSIS; MALE; PRIORITY JOURNAL; PROTEIN FOLDING; RNA SPLICING; RNA STABILITY; TH1 CELL; TH2 CELL;

ADULT; CHROMOSOMAL INSTABILITY; FEMALE; HUMANS; INTERLEUKIN-4; MALE; PROTEIN ISOFORMS; TH2 CELLS; TUBERCULOSIS, PULMONARY;

EID: 34047269240     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2006.11.001     Document Type: Article

References (31)

1. Dheda K., Chang J.S., Breen R.A., Kim L.U., Haddock J.A., Huggett J.F., et al. In vivo and in vitro studies of a novel cytokine, interleukin-4delta2, in pulmonary tuberculosis. Am J Respir Crit Care Med 172 (2005) 501-508
2. Mazzarella G., Bianco A., Perna F., D'Auria D., Grella E., Moscariello E., et al. T lymphocyte phenotypic profile in lung segments affected by cavitary and non-cavitary tuberculosis. Clin Exp Immunol 132 (2003) 283
3. Ribeiro-Rodrigues R., Resende C.T., Johnson J.L., Ribeiro F., Palaci M., Sa R.T., et al. Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance. Clin Diagn Lab Immunol 9 (2002) 818
4. Hernandez-Pando R., Aguilar D., Hernandez M.L., Orozco H., and Rook G. Pulmonary tuberculosis in BALB/c mice with non-functional IL-4 genes: changes in the inflammatory effects of TNF-alpha and in the regulation of fibrosis. Eur J Immunol 34 (2004) 174
5. Hernandez-Pando R., Orozcoe H., Sampieri A., Pavon L., Velasquillo C., Larriva-Sahd J., et al. Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 89 (1996) 26
6. Hernandez-Pando R., and Rook G.A. The role of TNF-alpha in T-cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 82 (1994) 591
7. Ordway D.J., Costa L., Martins M., Silveira H., Amaral L., Arroz M.J., et al. Increased interleukin-4 production by CD8 and gammadelta T cells in health-care workers is associated with the subsequent development of active tuberculosis. J Infect Dis 190 (2004) 756
8. Seah G.T., Scott G.M., and Rook G.A. Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J Infect Dis 181 (2000) 385
9. van Crevel R., Karyadi E., Preyers F., Leenders M., Kullberg B.J., Nelwan R.H., et al. Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J Infect Dis 181 (2000) 1194
10. Rook G., Dheda K., and Zumla A. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol 5 (2005) 661-667
11. Rook G.A., Hernandez-Pando R., Dheda K., and Teng S.G. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 25 (2004) 483
12. Dlugovitzky D., Bottasso O., Dominino J.C., Valentini E., Hartopp R., Singh M., et al. Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Respir Med 93 (1999) 557-562
13. Demissie A., Abebe M., Aseffa A., Rook G., Fletcher H., Zumla A., et al. Healthy individuals that control a latent infection with M. tuberculosis express high levels of Th-1 cytokines and the IL-4 antagonist IL-4δ2. J Immunol 172 (2004) 6938-6943
14. Rook G.A., Dheda K., and Zumla A. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?. Vaccine 23 (2005) 2115
15. Atamas S.P., Choi J., Yurovsky V.V., and White B. An alternative splice variant of human IL-4, IL-4 delta 2, inhibits IL-4-stimulated T cell proliferation. J Immunol 156 (1996) 435
16. Vasiliev A.M., Vasilenko R.N., Kulikova N.L., Andreev S.M., Chikileva I.O., Puchkova G.Y., et al. Structural and functional properties of IL-4delta2, an alternative splice variant of human IL-4. J Proteome Res 2 (2003) 273
17. Dheda K., Chang J.S., Breen R.A., Haddock J.A., Lipman M.C., Kim L.U., et al. Expression of a novel cytokine, IL-4delta2, in HIV and HIV-tuberculosis co-infection. Aids 19 (2005) 1601-1606
18. Orsini B., Ottanelli B., Amedei A., Surrenti E., Capanni M., Del Prete G., et al. Helicobacter pylori cag pathogenicity island is associated with reduced expression of interleukin-4 (IL-4) mRNA and modulation of the IL-4delta2 mRNA isoform in human gastric mucosa. Infect Immun 71 (2003) 6664-6667
19. Atamas S.P., Yurovsky V.V., Wise R., Wigley F.M., Goter Robinson C.J., Henry P., et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 42 (1999) 1168
20. Bijlsma F.J., van Kuik J., van Hoffen E., de Jonge N., Tilanus M.G., Gmelig-Meyling F.H., et al. Acute cardiac transplant rejection is associated with low frequencies of interleukin-4 producing helper T-lymphocytes rather than with interleukin-4 promoter or splice variants. Hum Immunol 63 (2002) 317-323
21. Seah G.T., Gao P.S., Hopkin J.M., and Rook G.A. Interleukin-4 and its alternatively spliced variant (IL-4delta2) in patients with atopic asthma. Am J Respir Crit Care Med 164 (2001) 1016
22. Glare E.M., Divjak M., Bailey M.J., and Walters E.H. The usefulness of competitive PCR: airway gene expression of IL-5, IL-4, IL-4delta2, IL-2, and IFN-gamma in asthma. Thorax 56 (2001) 541-548
23. Dheda K., Huggett J.F., Bustin S.A., Johnson M.A., Rook G., and Zumla A. Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques 37 (2004) 112
24. Ross J. mRNA stability in mammalian cells. Microbiol Rev 59 (1995) 423-450
25. Dokter W.H., Esselink M.T., Sierdsema S.J., Halie M.R., and Vellenga E. Transcriptional and posttranscriptional regulation of the interleukin-4 and interleukin-3 genes in human T cells. Blood 81 (1993) 35-40
26. Dokter W.H., Sierdsema S.J., Esselink M.T., Halie M.R., and Vellenga E. Interleukin-4 mRNA and protein in activated human T cells are enhanced by interleukin-7. Exp Hematol 22 (1994) 74-79
27. Frevel M.A., Bakheet T., Silva A.M., Hissong J.G., Khabar K.S., and Williams B.R. p38 Mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Mol Cell Biol 23 (2003) 425-436
28. Umland S.P., Razac S., Shah H., Nahrebne D.K., Egan R.W., and Billah M.M. Interleukin-5 mRNA stability in human T cells is regulated differently than interleukin-2, interleukin-3, interleukin-4, granulocyte/macrophage colony-stimulating factor, and interferon-gamma. Am J Respir Cell Mol Biol 18 (1998) 631
29. Butler N.S., Monick M.M., Yarovinsky T.O., Powers L.S., and Hunninghake G.W. Altered IL-4 mRNA stability correlates with Th1 and Th2 bias and susceptibility to hypersensitivity pneumonitis in two inbred strains of mice. J Immunol 169 (2002) 3700-3709
30. Fijen J., Zijlstra J., De Boer P., Spanjersberg R., Tervaert J., AVan Der Werf T., et al. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol 124 (2001) 16-20
31. Kumar S., Boehm J., and Lee J.C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2 (2003) 717-726